S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits

Atherosclerosis

Volumn 183, Issue 1, 2005, Pages 65-73

  Worth, Nathalie F ^a   Berry, Celia L ^a   Thomas, Anita C ^a   Campbell, Julie H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Atherosclerosis; ICAM 1 expression; Macrophages; Restenosis; TP receptor antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; CHOLESTEROL; FAT; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PROSTAGLANDIN ENDOPEROXIDE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; S 18886; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERY INJURY; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CELL INFILTRATION; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; ILIAC ARTERY; INTIMA; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RESTENOSIS; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTIC DISEASES; ASPIRIN; ATHEROSCLEROSIS; BALLOON DILATATION; DIET, ATHEROGENIC; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; ILIAC ARTERY; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MALE; NAPHTHALENES; PLATELET AGGREGATION INHIBITORS; PROPIONIC ACIDS; RABBITS; RECEPTORS, THROMBOXANE; RECURRENCE; RUPTURE, SPONTANEOUS; TUNICA INTIMA; TUNICA MEDIA; VASCULITIS;

EID: 26244449273     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.02.034     Document Type: Article

References (31)

1. V. Fuster, B. Stein, and J.A. Ambrose Atherosclerotic plaque rupture and thrombosis Evolving Concepts Circ 82 1990 47 59
2. M.R. Garcia Palmieri The endothelium in health and in cardiovascular disease P R Health Sci J 16 1997 136 141
3. J.H. Ip, V. Fuster, and D. Israel The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty J Am Coll Cardiol 17 1991 77b 88b
4. A.J. Carter, L. Bailey, J. Devries, and B. Hubbard The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis Coron Artery Dis 11 2000 473 479
5. Antithrombotic-Trialists'-Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
6. W.S. Aronow Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease Drugs Aging 15 1999 91 101
7. W.L. Smith, E.A. Meade, and D.L. DeWitt Interactions of PGH synthase isozymes-1 and -2 with NSAIDs Ann N Y Acad Sci 744 1994 50 57
8. G.J. Hankey Current oral antiplatelet agents to prevent atherothrombosis Cerebrovasc Dis 11 Suppl 2 2001 11 17
9. P. Henriksson, M. Hamberg, and U. Diczfalusy Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall Biochim Biophys Acta 834 1985 272 274
10. A. Csiszar, G. Stef, P. Pacher, and Z. Ungvari Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets Prostaglandins Leukot Essent Fatty Acids 66 2002 557 558
11. D. Pratico, T. Cyrus, H. Li, and G.A. FitzGerald Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis Blood 96 2000 3823 3826
12. M.K. Halushka, and P.V. Halushka Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105 2002 1620 1622
13. S.L. Pfister, J.M. Schmitz, J.T. Willerson, and W.B. Campbell Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas Prostaglandins 36 1988 515 532
14. T. Ishizuka, M. Kawakami, and T. Hidaka Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells Clin Exp Immunol 112 1998 464 470
15. C. Patrono Aspirin resistance: definition, mechanisms and clinical readouts J Thromb Hemost 1 2003 1710 1713
16. M.J. Quinn, and D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
17. T.J. Verbeuren, S. Simonet, J.J. Descombes, R.A. Cohen, and G. Lavielle Pharmacology of S 18886 a new potent, long acting, orally active TP-receptor antagonist 2nd European congress of pharmacology. Budapest, Hungary Fundam Clin Pharmacol 1999
18. D. Yang, N. Levens, J.N. Zhang, P.M. Vanhoutte, and M. Félétou Specific potentiation of endothelium-dependent contractions in SHR by tetrahydrobiopterin Hypertension 41 2003 136 142
19. L. Belhassen, G. Pelle, J.-L. Dubois-Rande, and S. Adnot Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin J Am Coll Cardiol 41 2003 1198 1204
20. A.J. Cayatte, Y. Du, and J. Oliver Krasinski The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 1724 1728
21. Y. Cheng, S.C. Austin, and B. Rocca Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539 541
22. N.M. Caplice, P.A. Fennessy, J.A. Manderson, G.R. Campbell, and J.H. Campbell Rabbit models of atherosclerosis and restenosis F.P. Woodford J. Davignon A. Sniderman Atherosclerosis X 1995 Elsevier Amsterdam
23. B.E. Rolfe, S. Stamatiou, and C.J. World Leukaemia inhibitory factor retards the progression of atherosclerosis Cardiovasc Res 58 2003 222 230
24. K. Iiyama, L. Hajra, and M. Iiyama Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation Circ Res 85 1999 199 207
25. M.B. Taubman, J.T. Fallon, and A.D. Schecter Tissue factor in the pathogenesis of atherosclerosis Thromb Haemost 78 1997 200 204
26. S.E. Barnes, and P.D. Weinberg Contrasting patterns of spontaneous aortic disease in young and old rabbits Arterioscler Thromb Vasc Biol 18 1998 300 308
27. R. Virmani, F.D. Kolodgie, A.P. Burke, A. Farb, and S.M. Schwartz Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions Arterioscler Thromb Vasc Biol 20 2000 1262 1275
28. P. Libby, Y.J. Geng, and M. Aikawa Macrophages and atherosclerotic plaque stability Curr Opin Lipidol 7 1996 330 335
29. G.K. Sukhova, U. Schonbeck, and E. Rabkin Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques Circulation 99 1999 2503 2509
30. T.J. DeGraba Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque Neurology 49 1997 15 19
31. B.E. Rolfe, J.D. Muddiman, N.J. Smith, G.R. Campbell, and J.H. Campbell ICAM-1 expression by vascular smooth muscle cells is phenotype-dependent Atherosclerosis 149 2000 99 110